KISS1-derived reproductive neuropeptide / KISS1R agonist
Kisspeptin is one of the brain's upstream “start signals” for the reproductive hormone system. Human studies show that specific research forms can raise LH and FSH, trigger egg maturation during monitored IVF, and change sexual-processing signals in small controlled trials. It is not an approved fertility, testosterone, or sexual-function drug, and repeated exposure can make the hormone response fade.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Phase 2 IVF studies and multiple controlled physiology trials cover SubQ, IV, and intranasal kisspeptin, but most studies are small and no product is approved.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Acute LH and FSH responses are reproducible, while fertility, testosterone, sexual-function, and long-term safety conclusions remain preliminary and schedule dependent.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The IVF exposures occurred inside complete specialist-monitored stimulation and retrieval protocols. Repeated exposure produced a marked tachyphylaxis signal in hypothalamic amenorrhea, so isolated trial amounts are not a self-directed fertility, testosterone, or cycle protocol. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
Kisspeptin is one of the brain's upstream “start signals” for the reproductive hormone system. Human studies show that specific research forms can raise LH and FSH, trigger egg maturation during monitored IVF, and change sexual-processing signals in small controlled trials. It is not an approved fertility, testosterone, or sexual-function drug, and repeated exposure can make the hormone response fade.
Evidence reviewed through July 25, 2026. Kisspeptin-54 and kisspeptin-10, route-specific studies, acute hormone effects, clinical outcomes, and desensitization are separated.
What the evidence says
Phase 2 IVF oocyte-maturation studies and multiple small randomized controlled human physiology trials
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Comparative clinical effectiveness, long-term safety, durable fertility or symptom outcomes, optimal form and schedule, and product-specific identity and stability
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
LH rose five- to eightfold above baseline, then declined by 13% to 47% from its peak before the infusion ended; FSH and testosterone rose more modestly.
Intranasal kisspeptin-54 increased LH in all three groups, with the largest response in the hypothalamic-amenorrhea group. No side effects or adverse events were encountered during the short study.
Kisspeptin changed sexual-processing brain activity. Secondary analyses included up to 56% greater penile tumescence during a sexual video and improvement in selected desire or arousal measures.
Kisspeptin changed activity in brain regions involved in sexual and facial-attraction processing and was well tolerated during the acute visits.
Oocyte maturation occurred in 95% of women. Among 51 embryo transfers, biochemical pregnancy was 63%, clinical pregnancy 53%, and live birth 45%; no participant developed moderate, severe, or critical OHSS.
Administration and handling
Published human studies have used specific pharmaceutical kisspeptin-54 or kisspeptin-10 formulations by intravenous infusion, subcutaneous injection, or a study-specific intranasal spray. IVF studies placed one experimental trigger inside a full specialist-monitored stimulation, retrieval, fertilization, transfer, and luteal-support protocol. Hormone studies used short research visits with frequent blood sampling. These records explain what researchers tested; they do not establish a starter dose, conversion between forms, cycle, stack, testosterone protocol, fertility plan, or self-administration route.
No FDA-approved kisspeptin product label was located, so there is no official consumer reconstitution, diluent, storage, or beyond-use instruction to generalize. A 2025 paper reported up to 60 days of refrigerated stability for the investigators' specific pharmaceutical intranasal kisspeptin-54 formulation. That finding cannot validate another powder, vial, nasal product, mixture, or route, and it does not establish identity, purity, sterility, concentration, compatibility, or safe handling.
Primary-source ledger
2026-06-02 · PMID 42230485 · NCT01438073 · DOI 10.1007/s42000-026-00795-y
2025-05-01 · PMID 40215751 · DOI 10.1016/j.ebiom.2025.105689
2023-02-01 · PMID 36735255 · ISRCTN17271094 · DOI 10.1001/jamanetworkopen.2022.54313
2022-10-03 · PMID 36287566 · ISRCTN17271094 · DOI 10.1001/jamanetworkopen.2022.36131
2015-09-01 · PMID 26192876 · NCT01667406 · DOI 10.1210/jc.2015-2332
2014-08-01 · PMID 25036713 · NCT01667406 · DOI 10.1172/JCI75730
2014-06-01 · PMID 24517142 · DOI 10.1210/jc.2013-1569
2013-07-01 · PMID 23153270 · DOI 10.1111/cen.12103
2011-08-01 · PMID 21632807 · DOI 10.1210/jc.2011-0089
2009-11-01 · PMID 19820030 · DOI 10.1210/jc.2009-0406
2003-10-23 · PMID 14573733 · DOI 10.1056/NEJMoa035322